These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Moghaddam B; Javitt D Neuropsychopharmacology; 2012 Jan; 37(1):4-15. PubMed ID: 21956446 [TBL] [Abstract][Full Text] [Related]
25. Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia. Holcomb HH; Lahti AC; Medoff DR; Cullen T; Tamminga CA Neuropsychopharmacology; 2005 Dec; 30(12):2275-82. PubMed ID: 16034443 [TBL] [Abstract][Full Text] [Related]
26. Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies. Marsman A; van den Heuvel MP; Klomp DW; Kahn RS; Luijten PR; Hulshoff Pol HE Schizophr Bull; 2013 Jan; 39(1):120-9. PubMed ID: 21746807 [TBL] [Abstract][Full Text] [Related]
27. In vivo and ex vivo evidence for ketamine-induced hyperglutamatergic activity in the cerebral cortex of the rat: Potential relevance to schizophrenia. Kim SY; Lee H; Kim HJ; Bang E; Lee SH; Lee DW; Woo DC; Choi CB; Hong KS; Lee C; Choe BY NMR Biomed; 2011 Dec; 24(10):1235-42. PubMed ID: 21560175 [TBL] [Abstract][Full Text] [Related]
29. Multiprobe molecular imaging of an NMDA receptor hypofunction rat model for glutamatergic dysfunction. Kosten L; Verhaeghe J; Verkerk R; Thomae D; De Picker L; Wyffels L; Van Eetveldt A; Dedeurwaerdere S; Stroobants S; Staelens S Psychiatry Res Neuroimaging; 2016 Feb; 248():1-11. PubMed ID: 26803479 [TBL] [Abstract][Full Text] [Related]
30. Glutamatergic Deficits in Schizophrenia - Biomarkers and Pharmacological Interventions within the Ketamine Model. Haaf M; Leicht G; Curic S; Mulert C Curr Pharm Biotechnol; 2018; 19(4):293-307. PubMed ID: 29929462 [TBL] [Abstract][Full Text] [Related]
31. Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study. Stone JM; Erlandsson K; Arstad E; Squassante L; Teneggi V; Bressan RA; Krystal JH; Ell PJ; Pilowsky LS Psychopharmacology (Berl); 2008 Apr; 197(3):401-8. PubMed ID: 18176855 [TBL] [Abstract][Full Text] [Related]
32. [Role of astrocytes in alterations of glutamatergic neurotransmission in schizophrenia]. Kolomeets NS Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(1):110-117. PubMed ID: 25945378 [TBL] [Abstract][Full Text] [Related]
33. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Rowland LM; Bustillo JR; Mullins PG; Jung RE; Lenroot R; Landgraf E; Barrow R; Yeo R; Lauriello J; Brooks WM Am J Psychiatry; 2005 Feb; 162(2):394-6. PubMed ID: 15677610 [TBL] [Abstract][Full Text] [Related]
34. Nature of Glutamate Alterations in Schizophrenia: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies. Merritt K; Egerton A; Kempton MJ; Taylor MJ; McGuire PK JAMA Psychiatry; 2016 Jul; 73(7):665-74. PubMed ID: 27304221 [TBL] [Abstract][Full Text] [Related]
35. Glutamate in dorsolateral prefrontal cortex and auditory verbal hallucinations in patients with schizophrenia: A Ćurčić-Blake B; Bais L; Sibeijn-Kuiper A; Pijnenborg HM; Knegtering H; Liemburg E; Aleman A Prog Neuropsychopharmacol Biol Psychiatry; 2017 Aug; 78():132-139. PubMed ID: 28546056 [TBL] [Abstract][Full Text] [Related]
36. Direct and indirect modulation of the N-methyl D-aspartate receptor. Marino MJ; Conn PJ Curr Drug Targets CNS Neurol Disord; 2002 Feb; 1(1):1-16. PubMed ID: 12769631 [TBL] [Abstract][Full Text] [Related]
37. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Krystal JH; D'Souza DC; Mathalon D; Perry E; Belger A; Hoffman R Psychopharmacology (Berl); 2003 Sep; 169(3-4):215-33. PubMed ID: 12955285 [TBL] [Abstract][Full Text] [Related]
38. Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling. Noetzel MJ; Jones CK; Conn PJ Discov Med; 2012 Nov; 14(78):335-43. PubMed ID: 23200065 [TBL] [Abstract][Full Text] [Related]
39. Ketamine modulates hippocampal neurochemistry and functional connectivity: a combined magnetic resonance spectroscopy and resting-state fMRI study in healthy volunteers. Kraguljac NV; Frölich MA; Tran S; White DM; Nichols N; Barton-McArdle A; Reid MA; Bolding MS; Lahti AC Mol Psychiatry; 2017 Apr; 22(4):562-569. PubMed ID: 27480494 [TBL] [Abstract][Full Text] [Related]
40. Effect of L-theanine on glutamatergic function in patients with schizophrenia. Ota M; Wakabayashi C; Sato N; Hori H; Hattori K; Teraishi T; Ozawa H; Okubo T; Kunugi H Acta Neuropsychiatr; 2015 Oct; 27(5):291-6. PubMed ID: 25896423 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]